News & Updates

In the treatment of adults with uncontrolled focal seizures, the long-term, open-label use of cenobamate appears to produce high rates of sustained 100-percent and ≥90-percent seizure reduction, with parallel decreases in concomitant antiseizure medication (ASM) doses, according to two separate post hoc analyses of a phase III C021 trial.

Plasma choline pathway metabolites, including choline and betaine, appear to reduce the risks of cardiovascular events and recurrent stroke, as well as offer incremental value in risk discrimination and stratification in patients with ischaemic stroke, suggests a recent study.

Long-term postmarketing data for adjunctive brivaracetam show that its use helps improve seizure control in patients with various epilepsy syndromes, even in those with prior exposure to levetiracetam. However, psychobehavioural adverse events (AEs) occur in one out of ten patients.